Bluejay Diagnostics (BJDX) Common Equity (2020 - 2026)

Bluejay Diagnostics (BJDX) has 7 years of Common Equity data on file, last reported at $4.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 8.14% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.2 million (up 8.14% YoY), and the FY2025 full-year result was $6.0 million, up 4.29% from the prior year.
• Common Equity eased to $4.2 million in Q1 2026, from $6.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $18.5 million in Q1 2022 to a low of $2.9 million in Q4 2023.
• A 5-year average of $7.8 million and a median of $6.0 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 13389.68% in 2022 and plunged 74.92% in 2023, its largest moves.
• Tracing BJDX's Common Equity over 5 years: stood at $11.5 million in 2022, then sank by 74.92% to $2.9 million in 2023, then jumped by 97.92% to $5.7 million in 2024, then rose by 4.29% to $6.0 million in 2025, then tumbled by 30.03% to $4.2 million in 2026.
• Business Quant data shows BJDX's Common Equity at $4.2 million in Q1 2026, $6.0 million in Q4 2025, and $3.7 million in Q3 2025.